

Michelle Kang Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/136713/publications.pdf>

Version: 2024-02-01

39
papers

531
citations

840776

11
h-index

677142

22
g-index

40
all docs

40
docs citations

40
times ranked

735
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2212-2217.e1.	4.4	64
2	Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 184-192.	1.1	59
3	Diagnosis of Pancreatic Neuroendocrine Tumors. <i>Clinical Endoscopy</i> , 2017, 50, 537-545.	1.5	59
4	Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors. <i>Gut and Liver</i> , 2012, 6, 405-410.	2.9	54
5	Contributions of Adenocarcinoma and Carcinoid Tumors to Early-Onset Colorectal Cancer Incidence Rates in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 157-166.	3.9	51
6	Prognostic Significance of Lymph Node Metastases in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2015, 101, 58-65.	2.5	40
7	Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing. <i>Endocrine-Related Cancer</i> , 2019, 26, 47-57.	3.1	39
8	Neuroendocrine liver metastases: Value of apparent diffusion coefficient and enhancement ratios for characterization of histopathologic grade. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1432-1441.	3.4	21
9	The Role of Endoscopy in Small Bowel Neuroendocrine Tumors. <i>Clinical Endoscopy</i> , 2021, 54, 818-824.	1.5	14
10	Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 249-254.	1.1	13
11	Gender dynamics in education and practice of gastroenterology. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1047-1056.e5.	1.0	13
12	Survey Finds Gender Disparities Impact Both Women Mentors and Mentees in Gastroenterology. <i>American Journal of Gastroenterology</i> , 2021, 116, 1876-1884.	0.4	13
13	Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States. <i>Pancreas</i> , 2021, 50, 29-36.	1.1	12
14	Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria. <i>European Journal of Cancer</i> , 2017, 76, 197-204.	2.8	11
15	Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. <i>NAR Cancer</i> , 2020, 2, zcaa009.	3.1	11
16	Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients. <i>BMC Cancer</i> , 2021, 21, 146.	2.6	11
17	Shifts in the Proportion of Distant Stage Early-Onset Colorectal Adenocarcinoma in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 334-341.	2.5	10
18	Efficiency of cell-type specific and generic promoters in transducing oxytocin neurons and monitoring their neural activity during lactation. <i>Scientific Reports</i> , 2021, 11, 22541.	3.3	8

#	ARTICLE	IF	CITATIONS
19	Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis. <i>Pancreas</i> , 2019, 48, 131-134.	1.1	5
20	Gender in the endoscopy suite. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 1032-1034.	8.1	4
21	Farnesoid X Receptor Variant: A Sex-based Determinant of Crohn's Disease Progression. <i>Gastroenterology</i> , 2021, 160, 1866-1867.	1.3	4
22	Mentoring Disparities in Gastroenterology: The Path Forward. <i>Gastroenterology</i> , 2022, 162, 975-977.	1.3	3
23	Geographic Variation in Colorectal Cancer Incidence Among Asian Americans: A Population-Based Analysis 2006-2016. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 543-545.e3.	4.4	3
24	Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. <i>Pancreas</i> , 2016, 45, 528-532.	1.1	2
25	Cancer Beliefs Associated with Posttraumatic Stress Disorder in Neuroendocrine Tumor Survivors. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 369-373.	1.3	2
26	Adjunctive Molecular Analysis of Pancreatic Cyst Fluid to Determine Malignant Potential. <i>Gastroenterology</i> , 2015, 149, 249-251.	1.3	1
27	Predictors of recurrence in patients with surgically resected pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 408-408.	1.6	1
28	Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States from 1975 to 2012.. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-231.	1.6	1
29	Is Endoscopic Ultrasound-Fine Needle Aspiration for Ki67 Aspirational Enough?. <i>Clinical Endoscopy</i> , 2020, 53, 111-113.	1.5	1
30	Resection Prolongs Overall Survival for Nonmetastatic Midgut Small Bowel Neuroendocrine Tumors. <i>Pancreas</i> , 2022, 51, 171-176.	1.1	1
31	Understanding Autoimmune Pancreatitis Worldwide. <i>Gastroenterology</i> , 2014, 147, 1179-1180.	1.3	0
32	The Timing of a Diagnostic Colonoscopy After a Positive Fecal Immunochemical Test Result. <i>Gastroenterology</i> , 2019, 157, 261-262.	1.3	0
33	Perianal Goblet Cell Carcinoid With Pagetoid Spread. <i>International Journal of Surgical Pathology</i> , 2019, 27, 788-791.	0.8	0
34	Mentorship and women in gastroenterology. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 604-605.	8.1	0
35	Biomarkers in pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 166-166.	1.6	0
36	Pancreatic polypeptide as a biomarker for pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e21109-e21109.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Lymph node metastases in the prognosis of gastroenteropancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2016, 34, 224-224.	1.6	0
38	Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.. Journal of Clinical Oncology, 2018, 36, 502-502.	1.6	0
39	Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2019, 37, 105-105.	1.6	0